CEO still optimistic on new breast cancer drug
Send a link to a friend
[June 12, 2017] VIENNA
(Reuters) - Roche is convinced a new breast cancer drug will have a
significant role in treating the disease despite recent trial results
that disappointed analysts, the Swiss drugmaker's chief executive said
in an interview published on Sunday.
Trial results released last week showed mixing Perjeta with Roche's
established Herceptin treatment gave patients only a slight benefit.
The results hit Roche shares, and analysts said they increased the
chance of the company's revenues suffering when its $7
billion-a-year blockbuster Herceptin, which was approved in 1998, is
exposed to competition from cheaper rivals.
When asked whether he had been too optimistic on Perjeta and misled
investors in an update on the drug in March, Roche CEO Severin
Schwan said: "No."
"We are convinced that Perjeta will also play a significant role at
an early breast cancer stage, where healing is possible," he told
Swiss weekly Sonntagszeitung.
"The risk of suffering a relapse is reduced by nearly 20 percent by
Perjeta, on patients with a high risk of relapse even more."
Schwan said Roche's business was performing well and he was
confident the group would reach its full year targets.
[to top of second column]
Roche has a 2017 target for a low- to mid-single-digit increase in
sales, with similar growth in core earnings per share.
(Reporting by Kirsti Knolle; Editing by Mark Potter)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.